MacuLogix Appoints VP of Customer Experience
Robin Barnes Mattson joins MacuLogix as VP of Customer Experience
MIDDLETOWN, PA, November 10, 2017 – MacuLogix,® Inc., the only company to equip eye care professionals with the instrument, tools, and education needed to effectively diagnose and treat patients with age-related macular degeneration (AMD), announces that Robin Barnes Mattson has joined MacuLogix as VP of Customer Experience effective immediately. In this critical role, Ms. Mattson will be leading the team responsible for providing customers the tools and needed to revolutionize the management of AMD.
“Robin shares our goal of ensuring that our customers are absolutely thrilled about what we do for them, from the time we ship an AdaptDx®, through installation, training, integration, and optimization, and all of our post-sale customer service,” said William McPhee, President and CEO of MacuLogix.
Ms. Mattson is a proud alumnus of Miami University in Ohio and has a unique background encompassing sales, training, and implementation of utilization programs in the eye health sector. Most recently, she was Director of Training and Clinical Apps for Quidel Corp, a major American manufacturer of diagnostic healthcare products for hospitals, labs, and physicians’ offices. In that role, she launched an implementation department for the primary care and eye care markets worldwide.
“I am extremely excited to join a team with so much dedication to making customers a number one priority in the many months and years that follow each sale,” says Ms. Mattson. “I look forward to working with our experienced Practice Management Consultants to deliver the AMD Excellence Program that includes training, integration, and optimization of the AdaptDx.”
Ms. Mattson will work from Lake Bluff, IL, where she has lived with her husband and 3 children for many years. In her free time, she is an avid equestrian and FEI dressage rider.
MacuLogix, Inc. equips eye care professionals with the instrument, tools, and education needed to effectively diagnose and treat patients with AMD. By leveraging the science of dark adaptation through its AdaptDx, MacuLogix is working to eliminate preventable blindness caused by AMD, a chronic, progressive disease that impacts over 170 million people worldwide and goes undiagnosed in 25 percent of patients. Through its AdaptDx dark adaptation biomarker, MacuLogix enables eye care professionals to detect, monitor, and treat AMD three years before it can be seen clinically. MacuLogix provides in-practice training and treatment best practices to support the implementation and optimization of the AdaptDx.